Viewing Study NCT04746495


Ignite Creation Date: 2025-12-24 @ 2:16 PM
Ignite Modification Date: 2026-01-05 @ 5:25 PM
Study NCT ID: NCT04746495
Status: WITHDRAWN
Last Update Posted: 2023-02-21
First Post: 2021-01-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)
Sponsor: University of Michigan
Organization:

Study Overview

Official Title: Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)
Status: WITHDRAWN
Status Verified Date: 2023-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Issues relate to COVID-19 and staffing challenges, as well as very tight finances.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ENOVA
Brief Summary: This blinded cross-over clinical trial will enroll participants with mild stage 1 hypertension to evaluate whether urinary extracellular transcript abundance predicts response to an mineralocorticoid receptor (MR) antagonist, eplerenone.

Eligible participants will have a 2 week wash-in period followed by 4 weeks of treatment with placebo or eplerenone. There will be a 2 week wash out period from study medications and then participants will take the other drug (placebo or eplerenone) for 4 weeks. In addition, participants will also provide urine and blood samples during the trial, have physical assessments, and be monitored for safety.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
1K23HL128909-01A1 NIH None https://reporter.nih.gov/quic… View